CMO SAIC-F

Oncology

Dr. Barry L. Gause, MD

Barry L. Gause is an expert in the field of Oncology. Barry Gause is also published. He has 33 publications published. The lastest publication: "Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.'

Publications

Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma.
A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma.
Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and...
Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
Interactions between genetic and reproductive factors in breast cancer risk in a population-based sample of African-American families.
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell...
Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers.
A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma.
Phase i/ii trial of 5-Fluorouracil, leucovorin, Zidovudine and dipyridamole for patients with metastatic colorectal-cancer, renal-cell carcinoma and malignant-melanoma.
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.
The potential importance of swainsonine in therapy for cancers and immunology.
Protective effects of swainsonine on murine survival and bone marrow proliferation during cytotoxic chemotherapy.
A deletion linked to a poly(ADP-ribose) polymerase gene on chromosome 13q33-qter occurs frequently in the normal black population as well as in multiple tumor DNA.
In vivo treatment with monoclonal anti-I-A antibodies: disappearance of splenic antigen-presenting cell function concomitant with modulation of splenic cell surface I-...
Evaluation of recent trends in cancer mortality and incidence among blacks.
Descriptive analysis of breast cancer in African-American women at Howard University Hospital, 1960-1987.
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.
The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in c...
Treatment of relapsed Hodgkin''s disease.
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.
Interleukin 1 alpha increases serum leptin concentrations in humans.
Development of rheumatoid arthritis after treatment of large granular lymphocyte leukemia with deoxycoformycin.
A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma.
Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing ...
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia.
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.

Schools

Michigan State University

Doctors Specialties

Medical Oncology
Oncology

Accepted Insurances

Education

Michigan State University College of Human Medicine

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Dominick J. Memoli, MD This Doctor is OpenDoctor Recommended.
	Dr. Yudhishtra Markan, MD This Doctor is OpenDoctor Recommended.